Evidence map›Paper›PMID 39316581›Full record

ArticlePharmaceutical patent analyst2024

Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency.

Melody Okereke, Samson Ayorinde Oni, Zainab Ashimiyu-Abdusalam, Owolade Adedoyin John-Joy, Charles Diovu, Adeniyi Ayinde Abdulwahab, Adebayo Israel Jesutimilehin, Nwosu Ebube Clinton, Ibeh John Somtochukwu, Omojuyigbe Jeremiah Oluwamayowa and 2 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical patent analyst, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Melody OkerekeFaculty of Pharmaceutical Sciences, University of Ilorin, Kwara State, Nigeria.
Samson Ayorinde OniFaculty of Pharmaceutical Sciences, University of Ilorin, Kwara State, Nigeria.
Zainab Ashimiyu-AbdusalamDepartment of Biochemistry & Nutrition, Nigerian Institute of Medical Research, Nigeria.
Owolade Adedoyin John-JoyFaculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Nigeria.
Charles DiovuFaculty of Pharmaceutical Sciences, Enugu State University of Science & Technology, Enugu, Nigeria.
Adeniyi Ayinde AbdulwahabFaculty of Pharmaceutical Sciences, Bayero University, Kano, Nigeria.
Adebayo Israel JesutimilehinFaculty of Pharmacy, University of Lagos, Lagos, Nigeria.
Nwosu Ebube ClintonFaculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University, Igbariam, Anambra State, Nigeria.
Ibeh John SomtochukwuFaculty of Pharmacy, University of Lagos, Lagos, Nigeria.
Omojuyigbe Jeremiah OluwamayowaFaculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Nigeria.
Kawthar Olatunde OlaitanFaculty of Pharmaceutical Sciences, University of Ilorin, Kwara State, Nigeria.
Damilola Bodun SamuelDepartment of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsArtificial IntelligenceDrug DiscoveryMachine LearningPatents as TopicHumansNeoplasmsAntineoplastic Agentsactive learningartificial intelligencecancer drug discoverydeep learningdrug targetsinsilico methodsmachine learningpatentsquantitative structure activity relationshipvirtual screening

Identifiers

PMID39316581
PMCPMC11449019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.